Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Targeting hyperfibrinolysis: A novel prevention and reversal strategy.

Abd Alroof Higazi Nov 03, 2025 pp. 3055-3055 10.1182/blood-2025-3055

Abstract Activation of the fibrinolytic cascade is a common and difficult to manage cause of massive bleeding as in trauma, but available in...

Co-mapping clonal and transcriptional heterogeneity in somatic evolution via got-multi.

Minwoo Pak, Mirca Saurty-Seerunghen, Kellie Wise et al. Nov 03, 2025 pp. 244-244 10.1182/blood-2025-244

Abstract Somatic evolution drives cancer progression and therapy resistance. Underlying phenotypic progressions is the development of marked...

Treatment disparities in acute leukemia among patients with HIV: A nationwide analysis

Suriya Baskar, Fiqe Khan, Rodrigo Jose Hernandez et al. Nov 03, 2025 pp. 8097-8097 10.1182/blood-2025-8097

Abstract Treatment Disparities in Acute Leukemia Among Patients With HIV: A Nationwide Analysis Background Leukemia and HIV individually inv...

PU.1: C/EBPα ratio-directed reprogramming converts B-ALL cells into stable M1 macrophages for scalable cancer immunotherapy

Mengjie Li, Tianshuo Song, Zhiling Shi et al. Nov 03, 2025 pp. 4133-4133 10.1182/blood-2025-4133

Abstract Macrophages exhibit remarkable functional plasticity, making them a promising therapeutic tool against infections, cancers, and tis...

Evaluating a doctor-in-the-loop AI-agent for multiple myeloma chart reviews

Karla Mariana Castro Bórquez, Juan Pablo Capdevila, Jennifer Ahlstrom et al. Nov 03, 2025 pp. 4424-4424 10.1182/blood-2025-4424

Abstract Background: Real-world data (RWD) plays an increasingly important role in healthcare. Leveraging derived variables, such as lines-o...

CDK7 enables adaptive gene transcription required by stromal cells to support distinct T-cell lymphoma phenotypes and represents a novel microenvironment-directed therapeutic target

Khouloud Kouidri, Danilo Fiore, María Revuelta et al. Nov 03, 2025 pp. 554-554 10.1182/blood-2025-554

Abstract Over 75% of PTCL-NOS patients fail to achieve long-term control with current therapies, highlighting the need for novel therapeutic...

Retrospective evaluation of the G8 score in CLL patients treated with targeted therapies: A single-center experience

Alessandro Sanna, Chiara Maria Rapolla, Gabriella Carlomagno et al. Nov 03, 2025 pp. 2116-2116 10.1182/blood-2025-2116

Abstract Introduction: The evaluation of fitness status is a key factor in determining treatment strategies for Chronic Lymphocytic Leukemia...

Treatment free remission after asciminib (ABL001) based therapy in chronic Phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-h jean khoury cure CML consortium study HJKC3-0003

Michael Mauro, Lisa Rein, Jay Yang et al. Nov 03, 2025 pp. 7293-7293 10.1182/blood-2025-7293

Abstract Background: In a proportion of patients with chronic phase CML who achieve a sustained deep molecular remission (DMR), treatment di...

CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition

Kady Dennis, Sarah Parzych, Zachary Walker et al. Nov 03, 2025 pp. 5725-5725 10.1182/blood-2025-5725

Abstract Introduction: Multiple myeloma (MM) is an incurable plasma cell malignancy with increasing incidence in the United States. The appr...

Recreational use of nitrous oxide resulting in severe B12 deficiency, pancytopenia and hemolytic anemia

Yahye Farajuun Nov 03, 2025 pp. 2887-2887 10.1182/blood-2025-2887

Abstract Introduction: B12 deficiency is often seen in pernicious anemia, gastric surgeries, and strict vegetarian/vegan, but there are an i...

Outcomes for Medicare recipients with multiple myeloma: A national retrospective trend analysis from 2015 to 2022

Tony Elias, Danielle Thor, Ben Brik et al. Nov 03, 2025 pp. 8113-8113 10.1182/blood-2025-8113

Abstract Introduction: Despite global decreases in overall cancer incidence, the incidence of multiple myeloma (MM) continues to increase at...

Low CMV and EBV infections in the era of letermovir with post-transplantation cyclophosphamide combined with tacrolimus and low-dose post engraftment ATG as gvhd prophylaxis.

Wenhui Gao, Lining Wang, Ling Wang et al. Nov 03, 2025 pp. 4271-4271 10.1182/blood-2025-4271

Abstract Background Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is the standard curative therapy for high-risk hematologi...

Prognostic factors and therapeutic outcomes in neurolymphomatosis: A 22-year cohort study from Mayo Clinic

Ayo Falade, Abiola Bolarinwa, Oluwatayo Adeoye et al. Nov 03, 2025 pp. 6306-6306 10.1182/blood-2025-6306

Abstract Background Neurolymphomatosis (NL) is a rare and frequently underrecognized manifestation of lymphoma, characte...

Real-world rates of tyrosine kinase inhibitor prescription approval, fill, and adherence and associated factors in a national sample of patients with chronic myeloid leukemia

Pengxiang Li, Anoosha Shukla, John Lin et al. Nov 03, 2025 pp. 2651-2651 10.1182/blood-2025-2651

Abstract Background: Oral tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) into a manageable disease, enabl...

Racial disparities in mycosis fungoides - from self-reported race to genetic ancestry analysis

Viviane Liao, Prasath Pararajalingam, Cesar Virgen et al. Nov 03, 2025 pp. 5424-5424 10.1182/blood-2025-5424

Abstract Introduction: Racial disparities in mycosis fungoides (MF) and Sezary syndrome (SS) are well-documented, with self-identified Black...

Equalizing access to chimeric antigen receptor (CAR) T-cell therapies for myeloma patients

Ajay Nooka, Nishi Shah, Lawrence Boise et al. Nov 03, 2025 pp. 2823-2823 10.1182/blood-2025-2823

Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA) have resulted in improved...

Trial in progress: Phase II Study of (early) combination salvage therapy with venetoclax and intensified decitabine in relapsed/refractory AML (VenSwitch)

Lucas Mix, Jan Christian Schroeder, Osama Ahmad et al. Nov 03, 2025 pp. 8253-8253 10.1182/blood-2025-8253

Abstract Background and Significance Acute Myeloid Leukemia (AML) in the refractory or relapsed setting (r/r) has an unfavorable prognosis....

BT1: A CD84-targeting T-cell engager for selective eradication of leukemic stem cells in Acute Myeloid Leukemia

Ottavio Napolitano, Miso Park, Mariam Murtadha et al. Nov 03, 2025 pp. 3286-3286 10.1182/blood-2025-3286

Abstract Introduction: Acute myeloid leukemia (AML) is sustained by a subpopulation of leukemic stem cells (LSCs) that are resistant to conve...

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial

Mitin Nachu, Philip Stevenson, Kim Quach et al. Nov 03, 2025 pp. 5128-5128 10.1182/blood-2025-5128

Abstract BACKGROUND Treatment for adult ALL historically introduces toxicity and complexity that can be prohibitive for some patients (pts)....

Cost analysis compared with efficacy shows iron dextran surpassing other intravenous iron formulations in children: A tertiary children's hospital experience

Naik Mamta, Karen Williams, Samanta Catueno et al. Nov 03, 2025 pp. 6174-6174 10.1182/blood-2025-6174

Abstract Introduction Intravenous iron (IVI) therapy utilization for treatment of iron deficiency in children has increa...

Comparable survival with transplant-free approach versus autologous stem cell transplantation in adult relapsed/refractory classic Hodgkin lymphoma achieving complete remission

Panpan Liu, Caiyun Wang, Peng Sun et al. Nov 03, 2025 pp. 5397-5397 10.1182/blood-2025-5397

Abstract Introduction While high-dose therapy with autologous stem cell transplantation (HDT/ASCT) following salvage therapy remains the cur...

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

Kelly Chien, Ziyi Li, Marianne Zoghbi et al. Nov 03, 2025 pp. 2075-2075 10.1182/blood-2025-2075

Abstract Background: Hypomethylating agents (HMA) are the current standard-of-care for patients with myelodysplastic syndromes (MDS). Though...

Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia

Guillermo Montalban-Bravo, Chong Wu, Juan Jose Rodriguez-Sevilla et al. Nov 03, 2025 pp. 3849-3849 10.1182/blood-2025-3849

Abstract Recent updates to the monocyte count thresholds for diagnosing chronic myelomonocytic leukemia (CMML) have recognized oligomonocyti...

A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study

Nikita Dave, Imran Nizamuddin, Neha Mehta-Shah et al. Nov 03, 2025 pp. 1963-1963 10.1182/blood-2025-1963

Abstract Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplant. Therapies include reduction of i...

Hypercoagulability in clonal hematopoiesis: A hidden contributor to thrombosis in the elderly

FNU Anamika, Peter Wan, Marciano Figueroa Nov 03, 2025 pp. 6701-6701 10.1182/blood-2025-6701

Abstract Introduction: Clonal hematopoiesis (CH) is characterized by the expansion of hematopoietic cells bearing somati...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page